Article
Dynamic and rapid changes in viral quasispecies by UDPS in chronic hepatitis C patients receiving telaprevir-based therapy.
Antiviral therapy - 1 Jan 2013
Trimoulet Pascale, Pinson Patricia, Papuchon Jennifer, Foucher Juliette, Vergniol Julien, Chermak Faiza, Wittkop Linda, Castaing Nadège, Merrouche Wassil, Reigadas Sandrine, Molimard Mathieu, Kann Michael, Fleury Hervé, de Lédinghen Victor
Abstract excerpt
BACKGROUND: Telaprevir (TVR) is a protease inhibitor (PI) used in chronic hepatitis C treatment with pegylated interferon plus ribavirin. We analysed the prevalence and kinetic development of TVR resistance upon treatment. METHODS: A total of 24 cirrhotic patients (genotype 1a, n=8; genotype 1b, n=16) previously non-responders to standard therapy were treated with TVR-based therapy. The distribution of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
